Fundraising FoxVitro Biopharma
Golden, US · Nevada corporation
Find your way into Vitro Biopharma
Sign up to see every warm intro you have to Vitro Biopharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Vitro Biopharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Vitro Biopharma is a biotechnology company developing Wharton's jelly-derived (umbilical cord) mesenchymal stem cell therapies for autoimmune diseases and inflammatory disorders. It manufactures its cell therapy product candidates under cGMP conditions with ISO 9001:2015 and ISO 13485:2016 certification for the immunology and inflammation market.
Founders & leadership
JM
James MusickFounder
TO
Thomas OhrtExecutive
CF
Chris FurmanExecutive
TS
Tiana StatesChief Manufacturing Officer
NH
Nathan HaasCFO
Board
JP
John PacksBoard director
CM
Caroline MosessianBoard director
Reported raises · per SEC filings
Form D private placements$7.1M disclosed across 5 of 6 rounds · 2009–2025
▶$100KraisedJun 2025 · 1 investors · BiotechnologyRule 506(b)
▶$100KraisedJun 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John PacksDirector
- James MusickDirector
- Thomas OhrtExecutive Officer
- Chris FurmanExecutive Officer, Director
- Caroline MosessianDirector
- Offering amount
- $15M
- Amount sold
- $100K
- First sale
- May 2025
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$2MraisedDec 2023 · 1 investors · BiotechnologyRule 506(b)
▶$2MraisedDec 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tiana StatesExecutive Officer
- Nathan HaasExecutive Officer
- Christopher FurmanExecutive Officer, Director
- John PacksDirector
- James R MusickExecutive Officer, Director
- Caroline MosessianExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $2M
- First sale
- Nov 2023
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$992.6KraisedApr 2023 · 9 investors · BiotechnologyRule 506(b)
▶$992.6KraisedApr 2023 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tiana StatesExecutive Officer
- Caroline MosessianExecutive Officer, Director
- James R. MusickExecutive Officer, Director
- Nathan HaasExecutive Officer
- Christopher FurmanExecutive Officer, Director
- John PacksDirector
- Offering amount
- $2.5M
- Amount sold
- $992.6K
- First sale
- Jan 2023
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$3MraisedOct 2021 · 1 investors · BiotechnologyRule 506(b)
▶$3MraisedOct 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nathan HaasExecutive Officer
- Caroline MosessianDirector
- Jack ZamoraExecutive Officer, Director
- James MusickExecutive Officer, Director
- John EvansDirector
- Offering amount
- $10M
- Amount sold
- $3M
- First sale
- Oct 2021
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1MraisedOct 2020 · 10 investors · BiotechnologyRule 506(b)
▶$1MraisedOct 2020 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James MusickExecutive Officer, Director
- John EvansExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $1M
- First sale
- Jan 2020
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2000 | $100K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Vitro Biopharma do?
- Vitro Biopharma is a biotechnology company developing Wharton's jelly-derived (umbilical cord) mesenchymal stem cell therapies for autoimmune diseases and inflammatory disorders. It manufactures its cell therapy product candidates under cGMP conditions with ISO 9001:2015 and ISO 13485:2016 certification for the immunology and inflammation market.
- Who founded Vitro Biopharma?
- Vitro Biopharma was founded by James Musick.
- How much funding has Vitro Biopharma raised?
- Vitro Biopharma has disclosed $7.1M raised across 5 of its 6 known rounds.
- Where is Vitro Biopharma headquartered?
- Vitro Biopharma is headquartered in Golden, US.